Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Last trade$1.39
Day change+$0.19 (+15.83%)
Day range$1.19 – $1.52
Volume618,814
Market cap$92M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$91.97M
Price / earnings
—
Price / book
-16.22×
Price / sales
20.29×
EV / sales
18.06×
EV / EBITDA
-1.77×
Profitability
Earnings per share
-$1.26
Return on assets
-32.04%
Return on equity
1,703.6%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.1×
Current ratio
0.95×
Quick ratio
0.95×
Cash ratio
0.77×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CBUS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$800K
$994K
$1.68M
$1.06M
$615K
$933K
$1.03M
$1.21M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$800K
$994K
$1.68M
$1.06M
$615K
$933K
$1.03M
$1.21M
Selling, general and administrative
$5.39M
$5.41M
$5.08M
$5.13M
$5.27M
$6.65M
$9.86M
$6.8M
Research and development
$7.91M
$8.51M
$8.72M
$9.39M
$10.78M
$12.23M
$11.8M
$12.43M
Total operating expenses
$13.31M
$13.92M
$13.8M
$23.63M
$16.05M
$18.88M
$42.61M
$19.24M
Operating income
-$12.51M
-$12.93M
-$12.12M
-$22.57M
-$15.44M
-$17.95M
-$41.57M
-$18.02M
Interest expense
-$9.84M
-$9.48M
-$9.12M
-$9.41M
-$9.03M
-$8.67M
-$8.38M
-$8.24M
Income before taxes
-$21.94M
-$22.14M
-$21.22M
-$31.94M
-$24.31M
-$26.53M
-$49.39M
-$25.8M
Income taxes
$4K
$6K
$7K
$6K
-$6K
$27K
$2K
$6K
Net income
-$21.94M
-$22.15M
-$21.22M
-$31.95M
-$24.3M
-$26.56M
-$49.39M
-$25.8M
Net income attributable to common shareholders
-$21.94M
-$22.15M
-$21.22M
-$31.29M
-$23.54M
-$25.37M
-$46.89M
-$23.1M
EBITDA
-$11.41M
-$11.76M
-$10.92M
-$12.17M
-$14.02M
-$16.37M
-$18.99M
-$16.38M
Basic earnings per share
-$0.29
-$0.29
-$0.33
-$0.59
-$0.44
-$0.61
-$1.34
-$0.87
Diluted earnings per share
-$0.29
-$0.29
-$0.33
-$0.59
-$0.44
-$0.61
-$1.34
-$0.87
Recent news
Company coverage with links to the original publishers.
Cibus reported a quarterly loss of $0.29 per share, missing consensus estimates of $0.27, with revenues of $0.8 million falling 41.61% short of expectations. The stock has declined 33.3% year-to-date versus the S&P 500's 11.3% gain. With a Zacks Rank #3 (Hold) rating and the Agriculture - Operations industry ranking in the bottom 7%, the company faces headwinds despite slight improvement in losses compared to the prior year.
Dole reported quarterly earnings of $0.16 per share, missing consensus estimates of $0.31 by 48.39%, though revenues slightly exceeded expectations. The stock has underperformed the S&P 500 year-to-date. Cibus is expected to report results on November 12 with anticipated quarterly losses of $0.27 per share but significant revenue growth of 121% year-over-year.
Cibus, Inc. (Nasdaq: CBUS) announced the appointment of Craig Wichner, founder of Farmland LP, as Chief Executive Officer, with Peter Beetham transitioning to President and Chief Operating Officer. The leadership change is part of the company's succession planning strategy as it focuses on commercializing its gene-editing technology for plant traits. Wichner brings experience in farmland investment management and regenerative agriculture practices.
Cibus, Inc. has successfully transferred gene-edited herbicide tolerance traits in rice to its partner Interoc, marking a strategic milestone toward commercializing enhanced seed products in the Latin American market. The achievement demonstrates Cibus' ability to deliver traits on schedule using its Rapid Trait Development System, with expectations for additional gene-edited materials to be delivered to partners in the coming year as regulatory frameworks for gene editing continue to harmonize globally.
Cibus, Inc. has been selected as a key technology partner in a UK Government-funded research project to develop oilseed rape varieties with resistance to Light Leaf Spot disease, which has caused estimated yield losses of £300 million. The LLS-ERASED project will utilize Cibus' proprietary Rapid Trait Development System to create durable, multi-disease resistant varieties, involving 12 industry and academic partners including the John Innes Centre and University of Hertfordshire.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.